Methods for ameliorating infusion reactions
Certain embodiments of the invention provide methods of ameliorating an infusion reaction in a mammal in need thereof.
1. A method of ameliorating an infusion reaction associated with intravenous administration of at least one lipid formulated therapeutic agent in a mammal in need thereof, comprising administering to the mammal via injection a therapeutically effective amount of a nonsteroidal anti-inflammatory (NSAID) in combination with the lipid formulated therapeutic agent being intravenously administered, wherein the NSAID is ketorolac, wherein the lipid formulated therapeutic agent is formulated in a lipid nanoparticle (LNP), which LNP comprises the lipid formulated therapeutic agent, a cationic lipid, and a non-cationic lipid, and wherein the lipid formulated therapeutic agent is a nucleic acid, a polypeptide or an organic compound.
2. The method of claim 1 , wherein the infusion reaction comprises hypertension and/or hypotension.
3. The method of claim 2 , wherein the infusion reaction comprises hypertension followed by hypotension.
4. The method of claim 1 , wherein the infusion reaction comprises an increase in plasma thromboxane B2 levels.
5. The method of claim 1 , wherein the administration of the NSAID begins within about 2 hours prior to the administration of the at least one lipid formulated therapeutic agent.
6. The method of claim 1 , wherein the NSAID is ketorolac and is administered in a dose of about 15 mg to about 60 mg.
7. The method of claim 1 , wherein the NSAID is ketorolac and is administered in a dose of about 30 mg to about 60 mg.
8. The method of claim 1 , wherein the lipid formulated therapeutic agent is an antibody, siRNA or mRNA.
9. The method of claim 8 , wherein the lipid formulated therapeutic agent is siRNA.
10. The method of claim 8 , wherein the lipid formulated therapeutic agent is mRNA.
11. The method of claim 1 , further comprising administering an additional therapeutic agent.
12. The method of claim 11 , wherein the additional therapeutic agent is dexamethasone.
13. The method of claim 1 , wherein the NSAID is administered parenterally, intravenously, intramuscularly or subcutaneously.